ATE538809T1 - Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff - Google Patents
Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoffInfo
- Publication number
- ATE538809T1 ATE538809T1 AT04746847T AT04746847T ATE538809T1 AT E538809 T1 ATE538809 T1 AT E538809T1 AT 04746847 T AT04746847 T AT 04746847T AT 04746847 T AT04746847 T AT 04746847T AT E538809 T1 ATE538809 T1 AT E538809T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccine
- selecting appropriate
- biological sample
- precursor cells
- highly responsive
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000012472 biological sample Substances 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003184436 | 2003-06-27 | ||
JP2004070497 | 2004-03-12 | ||
PCT/JP2004/009378 WO2005001117A1 (ja) | 2003-06-27 | 2004-06-25 | Wt1ワクチン適応患者の選択方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE538809T1 true ATE538809T1 (de) | 2012-01-15 |
Family
ID=33554467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04746847T ATE538809T1 (de) | 2003-06-27 | 2004-06-25 | Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff |
Country Status (10)
Country | Link |
---|---|
US (1) | US10500257B2 (de) |
EP (3) | EP2343083B1 (de) |
JP (1) | JP4566912B2 (de) |
KR (2) | KR101292971B1 (de) |
CN (1) | CN1842603B (de) |
AT (1) | ATE538809T1 (de) |
CA (2) | CA2530184C (de) |
ES (3) | ES2443582T3 (de) |
HK (1) | HK1090093A1 (de) |
WO (1) | WO2005001117A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006602A1 (fr) * | 1998-07-31 | 2000-02-10 | Haruo Sugiyama | Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1 |
BRPI0208183B8 (pt) | 2001-03-22 | 2021-05-25 | Sugiyama Haruo | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer |
EP1550453B1 (de) * | 2002-09-12 | 2015-05-27 | International Institute of Cancer Immunology, Inc. | Präparat eines peptids eines krebs-antigens |
KR101292971B1 (ko) | 2003-06-27 | 2013-08-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 백신 적응 환자의 선택 방법 |
CN100513563C (zh) | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
WO2005095598A1 (ja) * | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
BRPI0607326B8 (pt) * | 2005-02-04 | 2021-05-25 | Survac Aps | composição de vacina, uso da referida composição e kit em partes |
CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
AU2006319892B2 (en) * | 2005-11-30 | 2012-05-10 | International Institute Of Cancer Immunology, Inc. | Novel peptide compound |
US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
JP2009538607A (ja) * | 2006-06-02 | 2009-11-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 患者が免疫療法に対する応答者であるかどうかを同定する方法 |
AU2008220031B2 (en) | 2007-02-27 | 2013-06-13 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
MX343633B (es) * | 2007-03-05 | 2016-11-11 | Int Inst Cancer Immunology Inc | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. |
AU2008332278C1 (en) | 2007-12-05 | 2013-10-03 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
AU2011313327B2 (en) | 2010-10-05 | 2015-10-22 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
WO2013002086A1 (ja) | 2011-06-28 | 2013-01-03 | 株式会社癌免疫研究所 | ペプチド癌抗原特異的t細胞のレセプター遺伝子 |
EP2561759A1 (de) | 2011-08-26 | 2013-02-27 | Bayer Cropscience AG | Fluoralkyl-substituierte 2-amidobenzimidazole und ihre Wirkung auf das Pflanzenwachstum |
UA114093C2 (xx) | 2011-09-16 | 2017-04-25 | Спосіб збільшення врожаю корисних рослин | |
WO2013037955A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Use of acylsulfonamides for improving plant yield |
BR112014006208B1 (pt) | 2011-09-16 | 2018-10-23 | Bayer Intellectual Property Gmbh | método de indução de respostas reguladoras do crescimento nas plantas aumentando o rendimento de plantas úteis ou plantas de cultura e composição de aumento do rendimento da planta compreendendo isoxadifen-etilo ou isoxadifeno e combinação de fungicidas |
US20150104413A1 (en) | 2012-01-13 | 2015-04-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
JP6273290B2 (ja) * | 2012-10-23 | 2018-01-31 | ユビバック エルエルシー | 疾患の処置のための同種異系のオートファゴソーム強化組成物 |
SG10201705028WA (en) | 2012-12-17 | 2017-07-28 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
EP3769782A1 (de) | 2013-01-15 | 2021-01-27 | Memorial Sloan Kettering Cancer Center | Immunogene wt-1-peptide und verfahren zur verwendung davon |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
CA2903624C (en) | 2013-03-05 | 2023-03-07 | Bayer Cropscience Aktiengesellschaft | Use of acylsulfonamides for improving plant yield |
BR112015021132B1 (pt) | 2013-03-05 | 2020-11-03 | Bayer Cropscience Aktiengesellschaft | uso de 1-metilhexil(5-cloro-8-quinolinóxi)acetato para induzir uma resposta de regulação de crescimento em plantas |
EP2981331B1 (de) * | 2013-03-28 | 2018-11-28 | Centre Hospitalier Universitaire de Montpellier | Verfahren zur bestimmung der strahlenempfindlichkeit |
CN111781359A (zh) * | 2013-05-13 | 2020-10-16 | 株式会社癌免疫研究所 | 用于预测免疫疗法的临床效果的方法 |
CN108431022B (zh) | 2015-11-20 | 2022-08-09 | 纪念斯隆凯特林癌症中心 | 用于治疗癌症的方法和组合物 |
EP3318135A1 (de) | 2016-11-03 | 2018-05-09 | Perfetti Van Melle S.p.A. | Sprudelndes süssigkeitenmaterial, verfahren zu dessen herstellung und daraus hergestellte produkte |
KR20230009426A (ko) * | 2020-05-12 | 2023-01-17 | 스미토모 파마 가부시키가이샤 | 암을 처치하기 위한 의약 조성물 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923799A (en) | 1984-02-06 | 1990-05-08 | The Ontario Cancer Institute | T cell specific cDNA clone |
US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
WO1993004695A1 (en) | 1991-08-28 | 1993-03-18 | The Wistar Institute | T cell receptor-based therapy for rheumatoid arthritis |
US5364787A (en) | 1992-03-23 | 1994-11-15 | Idaho Research Foundation | Genes and enzymes involved in the microbial degradation of pentachlorophenol |
WO1997039354A1 (fr) * | 1996-04-16 | 1997-10-23 | Kishimoto, Tadamitsu | Procede de detection de cellules solides cancereuses et d'heterotypie histologique et procede d'examen du tissu dans le but d'effectuer une transplantation de moelle osseuse et une transplantation de cellules souches du sang peripherique |
GB9710820D0 (en) | 1997-05-27 | 1997-07-23 | Univ Dundee | Immunological method |
US6013444A (en) | 1997-09-18 | 2000-01-11 | Oligotrail, Llc | DNA bracketing locus compatible standards for electrophoresis |
AU5528198A (en) | 1997-12-03 | 1999-06-16 | Immune Response Corporation, The | Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides |
ID28040A (id) | 1998-05-19 | 2001-05-03 | Avidex Ltd | Reseptor sel t yang dapat larut |
WO2000006602A1 (fr) | 1998-07-31 | 2000-02-10 | Haruo Sugiyama | Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1 |
US20030072767A1 (en) * | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
IL142216A0 (en) | 1998-09-30 | 2002-03-10 | Corixa Corp | A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same |
US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
HUP0202574A2 (en) | 1999-02-23 | 2002-12-28 | Baylor College Medicine | T cell receptor vbetha-dbetha-jbetha sequence and methods for its detection |
CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
US20050050580A1 (en) | 2000-12-13 | 2005-03-03 | Masashi Gotoh | Transgenic animal expressing hla-a24 and utilization thereof |
BRPI0208183B8 (pt) | 2001-03-22 | 2021-05-25 | Sugiyama Haruo | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer |
EP2014300B1 (de) | 2001-06-29 | 2011-01-12 | Chugai Seiyaku Kabushiki Kaisha | Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom |
CA2476995A1 (en) | 2001-09-18 | 2003-03-27 | Kyogo Itoh | Method of detecting cellular immunity and application thereof to drugs |
US8735357B2 (en) | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
US20050002951A1 (en) | 2001-09-28 | 2005-01-06 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
AU2003207528A1 (en) | 2002-01-09 | 2003-07-30 | Maxx Genetech Co. Ltd | Method of detecting t-cell proliferation for diagnosis of diseases by gene array |
AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
EP1550453B1 (de) | 2002-09-12 | 2015-05-27 | International Institute of Cancer Immunology, Inc. | Präparat eines peptids eines krebs-antigens |
WO2004063706A2 (en) | 2003-01-08 | 2004-07-29 | Maxx Genetech Co., Ltd. | Method of detecting over-expression of t-cell receptor genes by real-time pcr |
KR101292971B1 (ko) | 2003-06-27 | 2013-08-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 백신 적응 환자의 선택 방법 |
CN100513563C (zh) * | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
US20070238099A1 (en) | 2003-12-08 | 2007-10-11 | Cohen Irun R | Antigen Receptor Variable Region Typing |
US7576183B2 (en) | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
WO2005095598A1 (ja) * | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
GB0411771D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Nucleoproteins displaying native T cell receptor libraries |
GB0427585D0 (en) | 2004-12-16 | 2005-01-19 | Avidex Ltd | Assay |
WO2008026927A2 (en) | 2006-08-30 | 2008-03-06 | Academisch Medisch Centrum | Process for displaying t- and b-cell receptor repertoires |
MX343633B (es) | 2007-03-05 | 2016-11-11 | Int Inst Cancer Immunology Inc | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. |
JP2009278927A (ja) | 2008-05-23 | 2009-12-03 | Tohoku Univ | T細胞受容体を模倣する抗体断片及びその製造方法 |
WO2013002086A1 (ja) | 2011-06-28 | 2013-01-03 | 株式会社癌免疫研究所 | ペプチド癌抗原特異的t細胞のレセプター遺伝子 |
-
2004
- 2004-06-25 KR KR1020057024941A patent/KR101292971B1/ko active IP Right Grant
- 2004-06-25 ES ES11154325.2T patent/ES2443582T3/es active Active
- 2004-06-25 CA CA2530184A patent/CA2530184C/en not_active Expired - Fee Related
- 2004-06-25 EP EP11154325.2A patent/EP2343083B1/de not_active Not-in-force
- 2004-06-25 ES ES04746847T patent/ES2378156T3/es active Active
- 2004-06-25 US US10/562,486 patent/US10500257B2/en not_active Expired - Fee Related
- 2004-06-25 KR KR1020117006813A patent/KR101431312B1/ko active IP Right Grant
- 2004-06-25 WO PCT/JP2004/009378 patent/WO2005001117A1/ja active Application Filing
- 2004-06-25 ES ES11154327.8T patent/ES2478446T3/es active Active
- 2004-06-25 AT AT04746847T patent/ATE538809T1/de active
- 2004-06-25 CA CA2893995A patent/CA2893995A1/en not_active Abandoned
- 2004-06-25 JP JP2005511121A patent/JP4566912B2/ja not_active Expired - Fee Related
- 2004-06-25 EP EP04746847A patent/EP1640458B1/de not_active Not-in-force
- 2004-06-25 EP EP11154327.8A patent/EP2338509B1/de not_active Not-in-force
- 2004-06-25 CN CN2004800245592A patent/CN1842603B/zh not_active Expired - Fee Related
-
2006
- 2006-09-22 HK HK06110635.4A patent/HK1090093A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20060069363A (ko) | 2006-06-21 |
EP2338509B1 (de) | 2014-06-18 |
EP1640458A1 (de) | 2006-03-29 |
KR101431312B1 (ko) | 2014-08-20 |
KR20110049877A (ko) | 2011-05-12 |
ES2478446T3 (es) | 2014-07-22 |
JPWO2005001117A1 (ja) | 2006-08-10 |
ES2378156T3 (es) | 2012-04-09 |
EP2343083B1 (de) | 2014-01-15 |
CN1842603A (zh) | 2006-10-04 |
EP2343083A3 (de) | 2011-08-03 |
CA2530184C (en) | 2015-10-06 |
ES2443582T3 (es) | 2014-02-19 |
JP4566912B2 (ja) | 2010-10-20 |
HK1090093A1 (en) | 2006-12-15 |
EP2338509A2 (de) | 2011-06-29 |
EP1640458B1 (de) | 2011-12-28 |
EP2338509A3 (de) | 2011-11-30 |
KR101292971B1 (ko) | 2013-08-12 |
EP2343083A2 (de) | 2011-07-13 |
WO2005001117A1 (ja) | 2005-01-06 |
US20070128207A1 (en) | 2007-06-07 |
CA2530184A1 (en) | 2005-01-06 |
CA2893995A1 (en) | 2005-01-06 |
US10500257B2 (en) | 2019-12-10 |
EP1640458A4 (de) | 2008-05-21 |
CN1842603B (zh) | 2013-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE538809T1 (de) | Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff | |
ATE353974T1 (de) | Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs | |
WO2004113912A8 (en) | System and method for determining a temperature during analysis of biological fluid | |
DE60039310D1 (de) | Verfahren zur bestimmung von amyloidogenen proteinen | |
ATE429640T1 (de) | Diagnostischer assay zur bestimmung einer zellvermittelten immunantwort | |
RU2007141067A (ru) | Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях | |
TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
DE60138829D1 (de) | Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker | |
MX342791B (es) | Ensayo elisa para la detección de vegf. | |
JP2014512006A5 (de) | ||
ATE184703T1 (de) | Verfahren und testsatz zur messung von endogenen zytokinen | |
AR071034A1 (es) | Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor | |
ATE514951T1 (de) | Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse | |
DE602005013430D1 (de) | Verwendung von asc als marker für kolorektalkarzinome | |
ATE550668T1 (de) | Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis | |
ATE520987T1 (de) | Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum | |
HUP0203408A2 (hu) | Eljárás hiperlipémia elleni preventív vagy terápiás hatóanyag tesztelésére | |
ATE314648T1 (de) | Diagnostisches verfahren für asthma | |
DE10391021D2 (de) | Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens | |
ATE412180T1 (de) | Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten | |
ATE547534T1 (de) | Verfahren zur nichtinvasiven untersuchung nicht- alkoholischer steatohepatitis mittels quantifizierung von cytochrom-c | |
ATE499611T1 (de) | Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i | |
BR0209681A (pt) | Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente | |
Cummins et al. | Raman spectroscopy of fingernails: A novel tool for evaluation of bone quality? | |
Ombandza-Moussa et al. | Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode |